Evidence map›Paper›PMID 42323321›Full record

ArticleCell death discovery2026

Newly identified invasion drivers define the tumor front in oral squamous cell carcinoma.

Guillermo Flores, Slyn Uaroon, Juan A R Garay, Marion Vanneste, Jesse D Riordan, Adam J Dupuy, Kristina W Thiel, Kaitriana E Colling, Christopher S Stipp, Li-Chun Lin and 14 more

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Guillermo FloresDepartment of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, IA, USA. gflrs@uiowa.edu.ORCID http://orcid.org/0000-0002-2160-7229
Slyn UaroonHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Juan A R GarayHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Marion VannesteHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Jesse D RiordanHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Adam J DupuyHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Kristina W ThielHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Kaitriana E CollingHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Christopher S StippHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Li-Chun LinIowa NeuroBank Core, Iowa Neuroscience Institute, Carver College of Medicine, Iowa City, IA, USA.
Bailey HollisIowa NeuroBank Core, Iowa Neuroscience Institute, Carver College of Medicine, Iowa City, IA, USA.
Mariah R LeidingerUniversity of Iowa Institute for Vision Research, Iowa City, IA, USA.
Stephanie J T ChenDepartment of Pathology, University of Iowa Hospitals & Clinics, Iowa City, IA, USA.
Lillian M GrahamDepartment of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, IA, USA.
Kevin L KnudtsonIowa Institute of Human Genetics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID http://orcid.org/0000-0003-1788-4933
Michael S ChimentiIowa Institute of Human Genetics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Jason A RatcliffIowa Institute of Human Genetics, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Zain MehdiCarver College of Medicine, University of Iowa, Iowa City, IA, USA.
Madison C McElliottDepartment of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA.
Eric R AndersonDepartment of Biology, University of Iowa, Iowa City, IA, USA.
Michael D HenryHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Molly E Heft NealDepartment of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA.
J Chad BrennerDepartment of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-3238-1111
Marisa R BuchakjianDepartment of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA.

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Research Training Program in OtolaryngologyT32DC000040 · NIDCD · UNIVERSITY OF IOWA · PI HANSEN, MARLAN R · 1993 to 2025
$5.4M
American Cancer Society (American Cancer Society, Inc.) IRG-21-141-46NCI NIH HHS P30 CA086862NIDCD NIH HHS T32 DC000040U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD) 5T32DC000040-28U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) P30CA086862
6 · The paper itself

Abstract

Cells at the invasive front of oral squamous cell carcinoma (OSCC) occupy a partial epithelial-to-mesenchymal transition (p-EMT) state that drives invasion and therapeutic resistance yet remains poorly understood. To define the regulators of this metastable state, we developed an isogenic OSCC model that captures stable epithelial and p-EMT phenotypes and used it to perform a genome-wide CRISPR invasion screen. This unbiased strategy identified 17 modulators of invasion, most previously unrecognized in cancer and virtually unexplored in OSCC, that converge on cytoskeletal remodeling, adhesion, and epigenetic regulation. Within this network, EDIL3 emerged as a central driver of EMT, invasion, and chemoresistance in head and neck cancer, extending prior reports in other tumor types. Importantly, the invasion signature derived from our screen localized with striking specificity to the tumor invasive front of human OSCC, providing direct clinical validation. Together, these findings reveal a novel, targetable network of transient invasion drivers defining the OSCC tumor front.

Identifiers

PMID42323321
PMCPMC13530252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.